MCID: BRD004
MIFTS: 53

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 74 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD9CM 34 301.83
MeSH 43 D001883
NCIt 49 C92633
SNOMED-CT 67 20010003
ICD10 32 F60.3
UMLS 71 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to avoidant personality disorder and impulse control disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Dopamine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.9 TPH1 SLC6A4 SLC6A3 MAOA HTR1B
2 impulse control disorder 31.5 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
3 alexithymia 31.1 SLC6A4 HTR1A DRD2 COMT
4 dissociative disorder 31.1 SLC6A4 HTR2A BDNF
5 somatization disorder 31.0 SLC6A4 HTR2A CRH
6 obsessive-compulsive personality disorder 31.0 SLC6A4 HTR2A COMT
7 amnestic disorder 30.9 HTR1A DRD2 BDNF
8 dysthymic disorder 30.8 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
9 body dysmorphic disorder 30.8 SLC6A4 MAOA HTR2A
10 cyclothymic disorder 30.8 HTR2A DRD2 COMT
11 acute stress disorder 30.7 SLC6A4 NR3C1 FKBP5 CRHR1 CRH BDNF
12 galactorrhea 30.7 PRL DRD2
13 traumatic brain injury 30.7 DRD2 COMT BDNF
14 somatoform disorder 30.6 TPH1 SLC6A4 CRH COMT BDNF
15 conduct disorder 30.6 TPH1 SLC6A4 SLC6A3 MAOA DRD2 COMT
16 antisocial personality disorder 30.5 SLC6A4 SLC6A3 PRL MAOA HTR2A HTR1B
17 brain injury 30.5 DRD2 COMT BDNF
18 neurotic disorder 30.5 SLC6A4 MAOA HTR2A HTR1A BDNF
19 hypochondriasis 30.4 SLC6A4 HTR2C HTR2A HTR1A BDNF
20 polysubstance abuse 30.3 DRD2 COMT
21 tardive dyskinesia 30.3 HTR2A DRD2 COMT
22 depression 30.3 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
23 social phobia 30.2 SLC6A4 PRL MAOA HTR1A DRD2 COMT
24 schizoaffective disorder 30.2 SLC6A4 PRL HTR2A HTR1A DRD2 COMT
25 adjustment disorder 30.2 SLC6A4 HTR2A HTR1A BDNF
26 phobia, specific 30.2 SLC6A4 MAOA HTR1A CRH COMT
27 agoraphobia 30.1 SLC6A4 MAOA HTR2A HTR1A CRH COMT
28 heroin dependence 30.1 SLC6A4 SLC6A3 MAOA DRD2 COMT BDNF
29 oppositional defiant disorder 30.1 TPH2 SLC6A4 SLC6A3 MAOA DRD2 COMT
30 opioid addiction 30.1 DRD2 COMT
31 asperger syndrome 30.1 SLC6A4 COMT BDNF AVPR1A
32 eating disorder 30.0 SLC6A4 SLC6A3 HTR2C HTR2A DRD2 CRHR2
33 sleep apnea 30.0 SLC6A4 HTR2C HTR2A BDNF
34 constipation 30.0 TPH1 SLC6A4 HTR2A HTR1A BDNF
35 schizophreniform disorder 29.9 PRL HTR2A DRD2 COMT BDNF
36 hyperprolactinemia 29.9 PRL HTR2C HTR2A DRD2
37 bulimia nervosa 29.9 SLC6A4 PRL MAOA HTR2C HTR2A HTR1B
38 intermittent explosive disorder 29.8 SLC6A4 MAOA HTR2C HTR2A HTR1A DRD2
39 bipolar i disorder 29.8 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
40 melancholia 29.8 SLC6A4 PRL MAOA HTR2A HTR1A CRH
41 withdrawal disorder 29.8 HTR1A DRD2 CRHR1 CRH
42 fibromyalgia 29.8 SLC6A4 PRL HTR2A HTR1A DRD2 CRH
43 substance-induced psychosis 29.8 SLC6A3 HTR2A HTR1A DRD2 COMT
44 dementia 29.7 SLC6A3 HTR2A HTR1A DRD2 COMT BDNF
45 sleep disorder 29.7 SLC6A4 SLC6A3 PRL HTR2C HTR2A HTR1A
46 anorexia nervosa 29.7 TPH1 SLC6A4 PRL MAOA HTR2C HTR2A
47 opiate dependence 29.7 TPH1 SLC6A4 SLC6A3 DRD2 CRH
48 postpartum depression 29.7 SLC6A4 PRL NR3C1 MAOA HTR1A CRH
49 drug dependence 29.6 SLC6A4 SLC6A3 DRD2 CRHR2 CRHR1 CRH
50 restless legs syndrome 29.6 SLC6A4 SLC6A3 PRL MAOA DRD2 COMT

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

GenomeRNAi Phenotypes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.55 MAOA NR3C1
2 Decreased viability GR00240-S-1 9.55 COMT
3 Decreased viability GR00249-S 9.55 COMT CRHR1 SLC6A4 TPH1
4 Decreased viability GR00381-A-1 9.55 AVPR1A HTR1A SLC6A4
5 Decreased viability GR00381-A-3 9.55 HTR1A SLC6A4
6 Decreased viability GR00386-A-1 9.55 COMT FKBP5 TPH2
7 Decreased viability GR00402-S-2 9.55 HTR1A TPH2

MGI Mouse Phenotypes related to Borderline Personality Disorder:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 AVPR1A BDNF COMT CRH CRHR1 CRHR2
2 homeostasis/metabolism MP:0005376 10.36 AVPR1A BDNF COMT CRH CRHR1 CRHR2
3 endocrine/exocrine gland MP:0005379 10.33 AVPR1A BDNF COMT CRH CRHR1 CRHR2
4 cardiovascular system MP:0005385 10.26 AVPR1A COMT CRHR1 CRHR2 DRD2 HTR1A
5 nervous system MP:0003631 10.17 AVPR1A BDNF COMT CRH CRHR1 DRD2
6 adipose tissue MP:0005375 10.11 CRH CRHR2 DRD2 HTR1B HTR2C NR3C1
7 integument MP:0010771 10.1 BDNF CRH DRD2 HTR2C NR3C1 PRL
8 muscle MP:0005369 10.02 AVPR1A DRD2 HTR1B HTR2A HTR2C NR3C1
9 normal MP:0002873 9.9 AVPR1A BDNF CRH CRHR1 DRD2 FKBP5
10 no phenotypic analysis MP:0003012 9.86 BDNF CRH CRHR1 DRD2 HTR1A HTR1B
11 respiratory system MP:0005388 9.56 BDNF COMT CRH CRHR1 DRD2 NR3C1
12 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6 Omega 3 Fatty Acid Phase 4
7 Neurotransmitter Agents Phase 4
8 Dopamine Agents Phase 4
9 Serotonin Uptake Inhibitors Phase 4
10 Sodium Channel Blockers Phase 4
11 Diuretics, Potassium Sparing Phase 4
12 Calcium, Dietary Phase 4
13 calcium channel blockers Phase 4
14 Dopamine Antagonists Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 6436173 46783403
19
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
20
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
21
Brexpiprazole Approved, Investigational Phase 2, Phase 3 913611-97-9 11978813
22
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
23 Anti-Infective Agents Phase 2, Phase 3
24 Antitubercular Agents Phase 2, Phase 3
25 Anti-Bacterial Agents Phase 2, Phase 3
26 Sulfalene Phase 2, Phase 3
27 Antibiotics, Antitubercular Phase 2, Phase 3
28 Gastrointestinal Agents Phase 3
29 Antiemetics Phase 3
30 Quetiapine Fumarate Phase 3 111974-72-2
31 Antiparkinson Agents Phase 3
32 Neuroprotective Agents Phase 3
33 Monoamine Oxidase Inhibitors Phase 3
34 Dopamine agonists Phase 2, Phase 3
35 Narcotics Phase 3
36 Analgesics, Opioid Phase 3
37 Narcotic Antagonists Phase 3
38
Acetaminophen Approved Phase 2 103-90-2 1983
39
Ziprasidone Approved Phase 2 146939-27-7 60854
40
Lithium carbonate Approved Phase 2 554-13-2
41
Cocaine Approved, Illicit Phase 2 50-36-2 446220 5760
42
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
43
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
44
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
45
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
46
Ketamine Approved, Vet_approved Phase 2 6740-88-1 3821
47
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
48
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
49
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
50 Analgesics, Non-Narcotic Phase 2

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
4 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
5 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
6 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
7 Effect of Probiotics on Central Nervous System Functions in Humans Unknown status NCT02793193 Phase 2, Phase 3 Antibiotic
8 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo Completed NCT00088036 Phase 3 Olanzapine
9 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo Completed NCT00091650 Phase 3 Olanzapine;placebo
10 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
11 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
12 Seroquel XR for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
13 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
14 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder Recruiting NCT04186403 Phase 2, Phase 3 Brexpiprazole
15 Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial Recruiting NCT03677037 Phase 3
16 Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
17 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
18 Acetaminophen and Social Pain in Borderline Personality Disorder Unknown status NCT02108990 Phase 2 Acetaminophen
19 The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults Unknown status NCT00169884 Phase 2
20 Pilot Study of Central Meditation and Imagery Therapy for Borderline Personality Disorder Completed NCT02125942 Phase 1, Phase 2
21 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Completed NCT02728778 Phase 2 incobotulinumtoxin A
22 The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
23 Assessment and Treatment of Parasuicidal Patients Completed NCT00183651 Phase 2
24 Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study Completed NCT00635921 Phase 2 ziprasidone;Placebo
25 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
26 Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse Completed NCT00145678 Phase 2
27 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
28 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
29 Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial Completed NCT01456338 Phase 2
30 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
31 The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial Completed NCT01699997 Phase 2 Oxytocin;Placebo
32 A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder Recruiting NCT04100096 Phase 2 Brexpiprazole
33 A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder. Recruiting NCT03418675 Phase 2 Rexulti;Placebo
34 A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
35 Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
36 Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder Active, not recruiting NCT02003690 Phase 2 Pharmacotherapy
37 Multimodal Study of the Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder : Stress Reactivity and Functional Imaging Not yet recruiting NCT03209102 Phase 2
38 A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder Suspended NCT03395314 Phase 2 Ketamine;Midazolam
39 SSRIs and Self-harm in Borderline Personality Disorder Terminated NCT01103180 Phase 2 Escitalopram
40 Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse Terminated NCT01212588 Phase 2 mifepristone;Placebo
41 A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
42 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
43 Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD) Unknown status NCT00269139 Phase 1
44 Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder Completed NCT01193205 Phase 1
45 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
46 Effect of Fish Oil vs. Placebo on Subjective Effects of Alcohol in Healthy Humans Recruiting NCT03010917 Phase 1 Fish Oil with ethanol and placebo ethanol infusions;Placebo with ethanol and placebo ethanol infusions
47 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Suspended NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
48 Dialectical Behavioral Therapy for Patients With Borderline Personality Disorder Unknown status NCT00252031
49 Emotional Reaction of Patients With Borderline Personality Disorder (BPD)on Stimuli Connected to Self-injury - A Comparison Between Patients With BPD and a Healthy Control Group. Unknown status NCT03149926
50 A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients Unknown status NCT01602497

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

40
Brain, Testes, Amygdala, Cortex, Pituitary, Skin, Eye

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 6209)
# Title Authors PMID Year
1
Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder. 61 54
20146650 2010
2
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 54 61
19523495 2009
3
Interaction between gene variants of the serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) in borderline personality disorder. 61 54
18756498 2009
4
Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder. 54 61
17597424 2007
5
Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). 54 61
18004675 2007
6
Monoamine oxidase a gene is associated with borderline personality disorder. 61 54
17417058 2007
7
[Personality disorders in a nonclinical sample of adolescents]. 61 54
12506264 2002
8
Psychiatric comorbidity in compulsive sexual behavior disorder (CSBD). 61
32244085 2020
9
Insomnia in personality disorders and substance use disorders. 61
31778972 2020
10
Screening for alcohol use disorder among individuals with comorbid psychiatric disorders: Diagnostic accuracy in a sample of young Swiss men. 61
32135396 2020
11
Positive schemas in schema therapy with older adults: clinical implications and research suggestions. 61
32153260 2020
12
Goal-focused positive psychotherapy in action: A case study. 61
31926022 2020
13
Enhanced memory for negative social information in borderline personality disorder. 61
32437207 2020
14
Unified and disease specific alterations to brain structure in patients across six categories of mental disorders who experience own-thought auditory verbal hallucinations: A pilot study. 61
32298780 2020
15
Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis. 61
32348803 2020
16
Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. 61
32504127 2020
17
Emergency psychiatric management of borderline personality disorder: Towards an articulation of modalities for personalised integrative care. 61
32571544 2020
18
Intact Classical Fear Conditioning to Interpersonally Threatening Stimuli in Borderline Personality Disorder. 61
32535608 2020
19
Consider others better than yourself: Social decision-making and partner preference in Borderline Personality Disorder. 61
30458960 2020
20
A hierarchical analysis of the latent trait of borderline personality disorder and its possible clinical implications. 61
32360894 2020
21
Metacognitive improvement and symptom change in a 3-month treatment for borderline personality disorder. 61
30712326 2020
22
Exploring nonverbal synchrony in borderline personality disorder: A double-blind placebo-controlled study using oxytocin. 61
31774581 2020
23
The Relationship Among Shame, Nonsuicidal Self-Injury, and Suicidal Behaviors in Borderline Personality Disorder. 61
30654709 2020
24
Exploring the links among borderline personality disorder symptoms, trauma, and pain in patients with chronic pain disorders. 61
32569851 2020
25
Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study. 61
32521537 2020
26
Patients with borderline personality disorder and comorbid PTSD show biased attention for threat in the facial dot-probe task. 61
30563688 2020
27
Mobile App Integration Into Dialectical Behavior Therapy for Persons With Borderline Personality Disorder: Qualitative and Quantitative Study. 61
32525488 2020
28
A randomised trial of dialectical behaviour therapy and the conversational model for the treatment of borderline personality disorder with recent suicidal and/or non-suicidal self-injury: An effectiveness study in an Australian public mental health service. 61
32551819 2020
29
Efficacy of "Family Connections", a program for relatives of people with borderline personality disorder, in the Spanish population: study protocol for a randomized controlled trial. 61
32539740 2020
30
Autistic traits in mentalization-based treatment for concurrent borderline personality disorder and substance use disorder: Secondary analyses of a randomized controlled feasibility study. 61
31840273 2020
31
Modeling the suicidal behavior cycle: Understanding repeated suicide attempts among individuals with borderline personality disorder and a history of attempting suicide. 61
32162931 2020
32
The process of recovery and change in a dialectical behaviour therapy programme for youth. 61
32535985 2020
33
Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders. 61
32570249 2020
34
Psychiatric comorbidities and adverse childhood experiences in women with self-reported polycystic ovary syndrome: An Australian population-based study. 61
32361187 2020
35
Understanding empathy and its disorders through a focus on the neural mechanism. 61
32278184 2020
36
Striatal volumes as potential biomarkers in Eating Disorders: A pilot study. 61
32513624 2020
37
Unified protocol for anxiety disorders in two cities of Mexico measuring gamma activity: Study protocol for a randomized controlled trial. 61
32274440 2020
38
How Personality Disorders Change in Psychotherapy: a Concise Review of Process. 61
32519017 2020
39
Reciprocal Influences of Parent and Adolescent Borderline Personality Symptoms Over 3 Years. 61
32539621 2020
40
Developmental Pathways to BPD-Related Features in Adolescence: Infancy to Age 15. 61
32539619 2020
41
Caught in a web of trauma: Network analysis of childhood adversity and adult mental ill-health. 61
32562964 2020
42
Changing characteristics of a Psychiatric Emergency Care Centre. An eight year follow-up study. 61
29737196 2020
43
A preliminary evaluation of the effectiveness of dialectical behaviour therapy in a forensic psychiatric setting. 61
32483870 2020
44
The efficacy, safety and acceptability of emergency embedded Psychiatry Assessment and Planning Units: An evaluation of Psychiatry Assessment and Planning Units in close proximity to their associated emergency departments. 61
31973563 2020
45
Empathy, Alexithymia, and Theory of Mind in Borderline Personality Disorder. 61
32520852 2020
46
A unified model of shared brain structural alterations in patients with different mental disorders who experience own-thought auditory verbal hallucinations-A pilot study. 61
32304354 2020
47
Diffusion tensor imaging in borderline personality disorder showing prefrontal white matter alterations. 61
32473382 2020
48
Advance Directives: Another Gap in Services for People With Borderline Personality Disorder. 61
32354308 2020
49
Advance Directives: Another Gap in Services for People With Borderline Personality Disorder. 61
32354310 2020
50
Re-examining borderline personality disorder and substance use disorder: The role of emotion dysregulation. 61
32343289 2020

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 PRL NR3C1 HTR2C HTR2A HTR1D HTR1B
2
Show member pathways
12.95 HTR2C HTR2A DRD2 CRHR2 CRHR1 CRH
3 12.24 HTR1D HTR1B HTR1A DRD2 BDNF
5 12.07 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2A
6
Show member pathways
11.92 SLC6A3 MAOA DRD2 BDNF
7 11.87 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
8
Show member pathways
11.84 HTR2C HTR2A HTR1D HTR1B HTR1A DRD2
9 11.74 CRHR2 CRHR1 CRH
10
Show member pathways
11.72 TPH2 TPH1 MAOA
11 11.7 HTR2C HTR2A DRD2
12
Show member pathways
11.67 TPH2 TPH1 MAOA
13 11.65 PRL NR3C1 FKBP5
14
Show member pathways
11.39 TPH2 SLC6A4 SLC6A3 MAOA
15
Show member pathways
11.1 SLC6A4 SLC6A3 MAOA COMT
16
Show member pathways
11.04 TPH1 MAOA COMT
17 10.97 PRL HTR2C DRD2
18
Show member pathways
10.92 TPH2 SLC6A4 SLC6A3 MAOA HTR1B HTR1A
19
Show member pathways
10.81 MAOA COMT
20 10.74 MAOA COMT
21 10.72 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
22 10.45 CRHR2 CRHR1 CRH

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.27 SLC6A4 SLC6A3 MAOA HTR2C HTR2A HTR1D
2 synapse GO:0045202 9.95 SLC6A4 HTR2C HTR2A HTR1D HTR1A DRD2
3 integral component of plasma membrane GO:0005887 9.9 SLC6A4 SLC6A3 HTR2C HTR2A HTR1D HTR1B
4 neuron projection GO:0043005 9.83 TPH2 TPH1 SLC6A4 SLC6A3 CRHR1
5 axon GO:0030424 9.8 SLC6A3 HTR2A DRD2 CRHR2 COMT BDNF
6 integral component of postsynaptic membrane GO:0099055 9.56 SLC6A4 SLC6A3 HTR2A DRD2
7 dopaminergic synapse GO:0098691 9.48 SLC6A3 DRD2
8 serotonergic synapse GO:0099154 9.37 SLC6A4 HTR1B
9 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR2A HTR1B DRD2
10 dendrite GO:0030425 9.28 HTR2C HTR2A HTR1D HTR1B HTR1A DRD2

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.1 PRL HTR2A HTR1A CRH AVPR1A
2 G protein-coupled receptor signaling pathway GO:0007186 10.07 HTR2C HTR2A HTR1D HTR1B HTR1A DRD2
3 chemical synaptic transmission GO:0007268 9.95 HTR2C HTR2A HTR1D HTR1B HTR1A CRH
4 response to ethanol GO:0045471 9.89 SLC6A3 HTR1B DRD2 CRH
5 locomotory behavior GO:0007626 9.88 SLC6A3 HTR2C DRD2
6 memory GO:0007613 9.87 SLC6A4 HTR2A BDNF
7 female pregnancy GO:0007565 9.87 PRL CRHR1 CRH COMT
8 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 DRD2 CRHR2 CRHR1
9 circadian rhythm GO:0007623 9.86 TPH2 TPH1 SLC6A4 BDNF
10 negative regulation of cell death GO:0060548 9.85 DRD2 CRH BDNF
11 response to estrogen GO:0043627 9.83 TPH2 CRH COMT
12 regulation of synaptic vesicle exocytosis GO:2000300 9.83 HTR2A HTR1B DRD2
13 positive regulation of fat cell differentiation GO:0045600 9.82 TPH1 HTR2C HTR2A
14 release of sequestered calcium ion into cytosol GO:0051209 9.82 HTR2C HTR2A DRD2
15 response to cocaine GO:0042220 9.8 SLC6A3 HTR1B DRD2 CRH
16 regulation of dopamine secretion GO:0014059 9.79 HTR2A HTR1B DRD2
17 behavioral fear response GO:0001662 9.78 HTR2C HTR1A BDNF
18 activation of phospholipase C activity GO:0007202 9.77 HTR2A BDNF AVPR1A
19 signal transduction GO:0007165 9.77 PRL NR3C1 HTR2C HTR2A HTR1D HTR1B
20 feeding behavior GO:0007631 9.73 HTR2C HTR1B DRD2 BDNF
21 response to corticosterone GO:0051412 9.72 CRH AVPR1A
22 bone remodeling GO:0046849 9.72 TPH1 HTR1B
23 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD2 CRHR1
24 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.72 HTR2A HTR1B DRD2
25 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.72 HTR2C HTR2A HTR1D HTR1B HTR1A
26 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD2
27 dopamine metabolic process GO:0042417 9.71 DRD2 COMT
28 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A4 SLC6A3
29 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 AVPR1A
30 grooming behavior GO:0007625 9.71 DRD2 AVPR1A
31 regulation of behavior GO:0050795 9.71 HTR1D HTR1B HTR1A
32 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.71 HTR2A HTR1D HTR1B HTR1A
33 G protein-coupled receptor internalization GO:0002031 9.7 HTR1B DRD2
34 dopamine catabolic process GO:0042420 9.7 SLC6A3 MAOA COMT
35 catecholamine metabolic process GO:0006584 9.69 MAOA COMT
36 neurotransmitter catabolic process GO:0042135 9.69 MAOA COMT
37 regulation of dopamine metabolic process GO:0042053 9.69 SLC6A3 HTR1A
38 serotonin receptor signaling pathway GO:0007210 9.69 HTR2C HTR2A HTR1A
39 parturition GO:0007567 9.68 CRHR1 CRH
40 adenohypophysis development GO:0021984 9.68 SLC6A3 DRD2
41 monoamine transport GO:0015844 9.67 SLC6A4 SLC6A3
42 aromatic amino acid family metabolic process GO:0009072 9.67 TPH2 TPH1
43 hyaloid vascular plexus regression GO:1990384 9.67 SLC6A3 DRD2
44 drinking behavior GO:0042756 9.66 HTR1B DRD2
45 negative regulation of synaptic transmission, GABAergic GO:0032229 9.65 HTR1B BDNF
46 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.64 CRHR2 CRHR1
47 indolalkylamine biosynthetic process GO:0046219 9.63 TPH2 TPH1
48 sperm ejaculation GO:0042713 9.63 SLC6A4 AVPR1A
49 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.63 HTR1D HTR1B HTR1A
50 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.62 HTR2C HTR2A

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.97 HTR2C HTR2A HTR1D HTR1B HTR1A DRD2
2 peptide hormone binding GO:0017046 9.67 CRHR2 CRHR1 AVPR1A
3 neurotransmitter receptor activity GO:0030594 9.65 HTR2C HTR2A HTR1D HTR1B HTR1A
4 drug binding GO:0008144 9.55 SLC6A3 HTR2C HTR2A HTR1B DRD2
5 dopamine binding GO:0035240 9.52 SLC6A3 DRD2
6 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A4 SLC6A3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH2 TPH1
8 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.46 HTR2C HTR2A
9 corticotropin-releasing hormone receptor activity GO:0043404 9.43 CRHR2 CRHR1
10 corticotrophin-releasing factor receptor activity GO:0015056 9.4 CRHR2 CRHR1
11 tryptophan 5-monooxygenase activity GO:0004510 9.37 TPH2 TPH1
12 G protein-coupled serotonin receptor activity GO:0004993 9.35 HTR2C HTR2A HTR1D HTR1B HTR1A
13 serotonin binding GO:0051378 9.1 SLC6A4 HTR2C HTR2A HTR1D HTR1B HTR1A

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....